Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...

Richard Staines heard about this new strategy at the Veeva 2019 Commercial and Medical Summit, Europe. GSK’s approach to marketing content has had a major rethink in the last two years ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

Shares in GSK opened 1.9-percent lower in London following the results update. Over-the-counter treatment Zantac, known also by its non-commercial name ranitidine, was manufactured by several ...

GSK is delivering consistent financial performance ... So with that, I'll now hand over to Luke and Deborah to talk you through our commercial performance. Thanks, Emma. Please turn to the ...